close
close

Insider Buying: CEO of 908 Devices Inc. (NASDAQ:MASS) acquires 10,000 shares


908 Devices Inc. (NASDAQ:MASS – Get Free Report) CEO Kevin J. Knopp purchased 10,000 shares of 908 Devices in a transaction on Tuesday, May 7th. The shares were purchased at an average cost of $5.60 per share, for a total value of $56,000.00. Following the completion of the purchase, the CEO now owns 468,981 shares of the company’s stock, valued at approximately $2,626,293.60. The acquisition was disclosed in a document filed with the Securities and Exchange Commission, which can be accessed at this link.

908 Device Inventory Performance

NASDAQ MASS shares opened at $5.70 on Thursday. The company has a market capitalization of $187.99 million, a PE ratio of -5.30 and a beta of 1.02. 908 Devices Inc. it has a 1-year low of $4.85 and a 1-year high of $12.51. The company has a fifty-day moving average price of $6.45 and a 200-day moving average price of $7.08.

908 Devices (NASDAQ:MASS – Get Free Report) last announced its earnings results on Tuesday, April 30th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.03. 908 Devices had a negative net margin of 68.57% and a negative return on equity of 20.47%. The company had revenue of $9.99 million for the quarter, compared to analyst estimates of $9.29 million. During the same period last year, the company generated EPS ($0.39). The company’s revenues for this quarter increased by 5.3% compared to the same quarter last year. Stock research analysts predict that 908 Devices Inc. will record -1.11 EPS this year.

Hedge funds weigh 908 devices

Many large investors have recently modified their stake in the company. During the third quarter, Values ​​First Advisors Inc. increased its shares in 908 Devices companies by 24.5%. Values ​​First Advisors Inc. now owns 16,726 shares of the company’s stock valued at $111,000 after purchasing an additional 3,294 shares in the last quarter. The New York State Pension Fund increased its holdings in shares of 908 Devices by 5.0% during the fourth quarter. The New York State Retirement Fund now owns 74,033 shares of the company’s stock valued at $831,000 after purchasing an additional 3,508 shares in the last quarter. Arete Wealth Advisors LLC increased its holdings in 908 Devices by 35.8% during the third quarter. Arete Wealth Advisors LLC now owns 22,758 shares of the company’s stock valued at $152,000 after purchasing an additional 5,997 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of 908 Devices by 11.1% during the third quarter. Bank of New York Mellon Corp now owns 93,775 shares of the company’s stock valued at $625,000 after purchasing an additional 9,393 shares in the last quarter. Finally, the Florida Retirement System State Board acquired new shares of stock in 908 Devices during the first quarter worth approximately $80,000. 88.06% of the shares are currently held by institutional investors and hedge funds.

About 908 devices

(Get the free report)

908 Devices Inc, a commercial technology company, offers a variety of purpose-built handheld and benchtop mass spectrometry devices for the examination of unknown and invisible materials in life sciences research, bioprocessing, pharmaceutical/biopharmaceuticals, forensics and related markets. The company’s products include the MX908, a handheld, battery-powered Mass Spec instrument designed for the rapid analysis of solid, liquid, vapor and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information about the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate and total biomass in mammalian cell cultures, and provides process fingerprinting data to support large-scale efforts in prediction modeling of bioprocesses.

read more



Get daily news and ratings for 908 devices – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings for 908 Devices and related companies with MarketBeat.com’s FREE daily email newsletter.